Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of liver disease drugs, announced financial results Friday for the third quarter.
The company reported a net loss of $6.1 million, compared to $6.4 million for the third quarter of last year.
Research and development expenses were $4.1 million for the third quarter of 2015, compared with $4.4 million last year. The decrease in expenses for R&D was due to the decreased external clinical trial and manufacturing costs for the company’s drug candidate emricasan, which were offset by increased preclinical costs.
Cash, cash equivalents and marketable securities were $43.5 million as of Sept. 30, 2015, compared with $37.1 million as of Dec. 31, 2014.